Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

NCT06054191 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
BRAF V600 Mutation
MET Exon 14 Mutation

Interventions

DRUG: Dabrafenib + Trametinib
DRUG: Capmatinib

Sponsor

Sun Yat-sen University